Similarly, we investigated the potential neoantigens from the recurrent mutations of PTPRT. Some recurrent mutations (p.G826R and p.R1117C) of PTPRT were predicted to generate high-affinity neoantigens in pan-cancer that could be used as potential targets for immunotherapies in the future (Table 2). Here, PTPRT is linked to cancer.